Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

/p>

Deferred income, current (3.1) 3.1 -

Accrued share based payment

liability (122.9) 122.9 -

______ ___________ ____________

Net assets acquired at fair

value (348.6) 2,351.4 2,002.8

Goodwill 591.7

______ ___________ ____________

2,594.5

Total consideration satisfied

by:

Cash (including US$61.0 million

of direct costs of acquisition) 2,594.5

______ ___________ ____________

Fair value adjustments primarily relate to:

- the recognition of intangible assets totaling US$3,085.8 million, primarily represented by developed technology in respect of VYVANSE for the treatment of ADHD in paediatric patients in the US (US$1,133.3 million) and in-process research and development in respect of VYVANSE for non-paediatric patients in the US and VYVANSE in the RoW (US$1,943.3 million);

- deferred tax liabilities of US$1,110.6 million primarily in respect of temporary differences relating to recognised intangible assets; and

- elimination of liabilities relating to deferred revenue in respect of the New River Collaboration Agree
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... Md. , Dec. 22, 2014 /PRNewswire/ ... SYN), a developer of pathogen-specific therapies for ... on protecting the microbiome, today announced positive ... Phase 1a clinical trial of SYN-004, the ... prevention of Clostridium difficile (C. difficile) ...
(Date:12/22/2014)... 22, 2014  ( www.competitivehealth.com ) — Competitive Health ... bill review and advocacy service, has signed an agreement ... Savings discount health services marketplace. 63% of ... than they expected to pay. As part of an ... WellCard Savings is pleased to offer medical bill review ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... economic development in Dane County, Madison Gas & ... last 20 years as it works to nurture entrepreneurial ... tomorrow's major league employers. , ,For MG&E, it's part ... creating the right conditions for entrepreneurs by providing financial ...
... completed its previously announced acquisition of MARC Global Holdings, ... to 738 employees at 21 sites with $172 million ... MARC. , ,Former MARC CEO Oliver Cooper will have ... company leader John Jazwiec. , ,"The integration of MARC ...
... are pushing state restrictions on human embryonic stem ... beyond President Bush's 2001 order and put Wisconsin's ... ,Rather than adding a layer of unnecessary regulation, ... -- one federal and the other international -- ...
Cached Biology Technology:How MG&E bets on small companies for the long term 2How MG&E bets on small companies for the long term 3How MG&E bets on small companies for the long term 4Federal and global guidelines on stem cell research offer a level playing field 2Federal and global guidelines on stem cell research offer a level playing field 3
(Date:12/22/2014)... Dec. 22, 2014  The 2014 Holiday Season ... industry as Acuity Market Intelligence reports that the ... be open. Acuity forecasts that intensifying demand for ... incorporate biometrics will drive a global market of ... devices by 2020.   According to ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ... "Micro Market Monitor: North America Perimeter Security Systems ... http://photos.prnewswire.com/prnh/20130307/600769 The North American ... CAGR of 3.6% from 2014 to 2019. Although the ... Canada is expected to grow ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... conditions in California could be a gold mine to ... relationships and how these inner workings might apply on ... today on Science Online, researchers from the Department of ... California Berkeley describe a bacterial community that flourishes in ...
... shape the growth of engineered tissueCollagen often pops up ... collagen with a molecular hitchhiker, materials scientists at Johns ... researchers have found a simple new way to modify ... a treatment to block the formation of unwanted scar ...
... the marine bacterium Colwellia psychrerythraea 34H keeps very cool--typically ... in this frigid environment? To find out, scientists at ... sequenced and analyzed C. psychrerythraea's genome. , That genome ... of Sciences (PNAS) Online Early Edition July 25-29, reveals ...
Cached Biology News:ORNL, UC Berkeley unravel real-world clues to Earth's mysteries 2ORNL, UC Berkeley unravel real-world clues to Earth's mysteries 3Modified collagen could yield important medical applications 2Modified collagen could yield important medical applications 3Deep thinking: Scientists sequence a cold-loving marine microbe 2Deep thinking: Scientists sequence a cold-loving marine microbe 3